Radiopharm Theranostics今日宣布,其候选药物Rad301在针对胰腺导管腺癌患者的I期影像学临床试验中取得了令人振奋的积极结果。这一进展为该公司在肿瘤精准诊断领域的布局注入了新的动力。
Radiopharm Theranostics今日宣布,其候选药物Rad301在针对胰腺导管腺癌患者的I期影像学临床试验中取得了令人振奋的积极结果。这一进展为该公司在肿瘤精准诊断领域的布局注入了新的动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.